Premarket Mover: Recursion Pharmaceuticals Inc (RXRX) Up 2.13%

Recursion Pharmaceuticals Inc (RXRX) is higher by Thursday morning, with the stock increasing 2.13% in pre-market trading to 7.2. RXRX's short-term technical score of 49 indicates that the stock has traded less bullishly over the last month than 51% of stocks on the market. In the Biotechnology industry, which ranks 127 out of 146 industries, Recursion Pharmaceuticals Inc ranks higher than 68% of stocks. Recursion Pharmaceuticals Inc has risen 32.77% over the past month, closing at $5.23 on November 2. During this period of time, the stock fell as low as $5.23 and as high as $7.77. RXRX has an average analyst recommendation of Buy. The company has an average price target of $15.29.

RXRX has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on RXRX!

See Full RXRX Report

Recursion Pharmaceuticals Inc has a Long-Term Technical rank of 21. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 79% of the market scoring higher. In the Biotechnology industry which is number 130 by this metric, RXRX ranks better than 130% of stocks.

Important Dates for Investors in RXRX:

-Recursion Pharmaceuticals Inc is set to release earnings on 2024-02-07. Over the last 12 months, the company has reported EPS of $-1.46. -We do not have a set dividend date for Recursion Pharmaceuticals Inc at this time. Click Here To Get The Full Report on Recursion Pharmaceuticals Inc (RXRX)